Newsroom

Sera, Inc., a women’s healthcare company, announced today that Garrett K. Lam, M.D., FACOG, will be joining the company as chief medical officer on September 4, 2018. Dr. Lam will direct all clinical development activities for Sera as the company achieves its vision to be The Pregnancy Company™. He will lead a group of talented clinical operations professionals who support Sera’s collaborations with research teams across the globe.

June 19, 2018 — Sera announced today that the first patient has been enrolled in the AVERT PRETERM TRIAL. This is the second intervention study to use Sera’s PreTRM® test to identify women at high risk of early delivery that will receive proactive interventions with the goal of reducing the rate of premature delivery and improving newborn health. The principal investigator for the study is Matthew Hoffman, M.D., MPH, FACOG, Marie E. Pinizzotto, M.D., Endowed Chair of Obstetrics and Gynecology at Christiana Care Health System in Wilmington, Delaware.

May 29, 2018 – Intermountain Healthcare announced it is launching the first study of its kind that will use Sera’s PreTRM® to identify those at risk for premature birth, and, in those with high risk, to evaluate the impact of early interventions designed to prolong their pregnancy and reduce the rate of premature delivery.

Seattle, WA and Salt Lake City, February 12 – Sera, in collaboration with The Institute for Systems Biology and Integrated Diagnostics (Indi), today announced a paper entitled, “The building blocks of successful translation of proteomics to the clinic,” by Leroy Hood and colleagues published online in Current Opinion in Biotechnology.

SALT LAKE CITY, November 6, 2017–Sera today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Canaccord Genuity Medical Technologies and Diagnostics Forum in New York City. Dr. Critchfield’s presentation will take place at 2:30 PM E.T. on Thursday, November 9th, at the Westin Grand Central Hotel.

SALT LAKE CITY, September 5, 2017 –Sera today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming Baird Global Healthcare Conference in New York City. Dr. Critchfield’s presentation will take place at 9:05 AM E.T. on Thursday, September 7th, at the InterContinental New York Barclay Hotel.

SALT LAKE CITY, June 29, 2017– Sera, Inc., a women’s healthcare company, announced today that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Sera, Inc., based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.

SALT LAKE CITY, June 26, 2017– Sera, Inc., a women’s healthcare company, announced today that its recent analytical study, “Analytical Validation of Protein Biomarkers for Risk of Spontaneous Preterm Birth” has been published in the June issue of Clinical Mass Spectrometry. The study details a rigorous analytical validation of Sera’s liquid chromatography/mass spectrometry (LC/MS) platform for sensitive later-generation Agilent mass spectrometers. This work confirms Sera’s ability, across instrument generations, to perform accurate analytical measurements required to provide individualized determination of a woman’s risk of spontaneous early delivery through Sera’s groundbreaking PreTRM® test. The PreTRM® test is the first and only broadly clinically-validated blood test that provides an early and individualized prediction of preterm birth risk.

BURLINGTON, N.C. – May 23, 2017 – LabCorp® (NYSE: LH) today announced the nationwide availability the PreTRM® test. Developed by Sera, Inc., the PreTRM test is the first of its kind validated blood test that provides an early and individualized prediction of preterm birth risk for pregnant women. LabCorp and Sera previously announced their strategic collaboration for LabCorp to be the exclusive U.S. distributor of Sera’s PreTRM test. LabCorp was also a lead investor in Sera’s recently closed Series C financing round.

SALT LAKE CITY, May 17, 2017– Sera announced today that Nadia F. Altomare has joined the company as chief commercial officer. Ms. Altomare will lead all commercial activities for Sera as the company makes its groundbreaking PreTRM® test available to physicians and patients. The PreTRM test is the first and only broadly clinically-validated blood test that provides an early and individualized prediction of preterm birth risk.